The design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial
Open Access
- 9 April 2025
- journal article
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (9) , 538-553
Abstract
Objective: Chronic low back pain (cLBP) is a common condition that impacts quality of life and function. There are many evidence-based treatments to address cLBP; however, treatment effects are modest, perhaps in part due to individual variation in treatment response. The Biomarkers for Evaluating Spine Treatments (BEST) trial was designed as the collaborative centerpiece of the Back Pain Consortium (BACPAC) research program. This consortium was sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as part of the Helping to End Addiction Long-term (HEAL) Initiative. Design: The BEST trial was a sequential multiple assignment randomized trial (SMART) designed with the primary goal of identifying in whom different treatments show optimal response. The primary focus of the study was to use patient features, including biomarkers and phenotypic measures, to identify subsets of persons with cLBP who respond best to specific common treatments. Methods: Four interventions were chosen for the trial: Enhanced Self-Care, Acceptance and Commitment Therapy, Duloxetine, and Evidence-Based Exercise and Manual Therapy. Following a run-in period and baseline assessment, participants were randomized to 1 of the 4 treatments for the first 12-week intervention period. Participants were reassessed and based on their self-reported response to initial treatment, continued that initial treatment, were augmented with an additional randomly assigned treatment, or were switched to a new treatment. Conclusion: This trial was designed to deliver rich phenotypic data that will both potentially aid in the discovery of phenotypic characteristics that predict treatment response and provide a greater mechanistic understanding of cLBP. Clinical trial registration number: The Biomarkers for Evaluating Spine Treatments (BEST) trial is registered on ClinicalTrials.gov (Registration number: NCT05396014; https://clinicaltrials.gov/study/NCT05396014).Keywords
Funding Information
- National Institutes of Health (U24AR076730)
- The Back Pain Consortium
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health (U24AR076730, 1R21MD016467-01, 1K23AT011389-01A1, R01NS135833-01A1, RM1NS128956-01A1, R01DA058694-01)
- Department of Defense (W81XWH-21-PRMRP-CTA [PR212158])
This publication has 69 references indexed in Scilit:
- Feasibility randomized‐controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN studyEuropean journal of pain, 2021
- Patients’ Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practiceEuropean journal of pain, 2019
- Feasibility randomized‐controlled trial of online Acceptance and Commitment Therapy for patients with complex chronic pain in the United KingdomEuropean journal of pain, 2018
- Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination SurveyArthritis Care & Research, 2016
- The State of US Health, 1990-2010JAMA, 2013
- The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom SeverityArthritis Care & Research, 2010
- The Rising Prevalence of Chronic Low Back PainArchives of internal medicine (1960), 2009
- A primary care back pain screening tool: Identifying patient subgroups for initial treatmentArthritis Care & Research, 2008
- Validation and Utility of a Self-report Version of PRIME-MDThe PHQ Primary Care StudyJAMA, 1999
- Minimization: A new method of assigning patients to treatment and control groupsClinical Pharmacology & Therapeutics, 1974